

PharmaBridge Insights Report

Generated on: 2025-12-16 13:44:00

Query

I want to explore repurposing sildenafil for neuropathic pain. Give me a complete analysis including:
- Market opportunity for neuropathic pain - Patent landscape for sildenafil -
Current clinical trials for sildenafil - Any internal research we have on sildenafil

Data Sources

Publications: mock

Clinical Trials: mock

Patents: mock

Market (IQVIA): mock

Internal Knowledge: mock

Web Intelligence: mock

Generated at: 2025-12-16T08:13:56Z

Publications

Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine (2023)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 — Nature Reviews Endocrinology (2024)

Clinical Trials

NCT04566524 — A Research Study to See How Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (LEAN) [Phase 2] (Recruiting)

NCT04855081 — A Research Study to See How Well Semaglutide Works in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW) [Phase 3] (Active, not recruiting)

Patents

US10251836B2 — Acylated GLP-1 Compounds (exp: 2030-05-15)

US10722571B2 — Semaglutide Formulations (exp: 2035-03-10)

Market Insights (IQVIA)

Therapy Area: Metabolic (Obesity/Type 2 Diabetes)

CAGR: 22.5%

Market Size: \${'2022': 18.1, '2023': 22.4, '2024': 27.9}M

Key Competitors:

- Semaglutide (Novo Nordisk): 42.0%
- Tirzepatide (Eli Lilly): 28.0%
- Liraglutide (Novo Nordisk): 9.0%
- Oral Agents (SGLT2/DPP4): 14.0%

Internal Knowledge

- MINS Q3 Field Insights – Obesity Clinics: Clinicians report strong adherence at 12 weeks; nausea management protocols improve persistence.
- Strategy Deck – Incretins Competitive Positioning: Position semaglutide as metabolic platform therapy; defend share vs dual agonists with outcomes data

Web Intelligence

- ESC Guidelines: Updated cardiometabolic guidance emphasizes weight-centric management using GLP-1 RAs.
- FDA Drug Safety: No new GLP-1 RA safety communications; monitoring ongoing for pancreatitis and gallbladder events.
- Patient Forum (r/loseit): Users report plateau after 6 months; dose titration and lifestyle reinforcement recommended.

Key Insights

- Whitespace: High disease burden with low trial activity